Methadone News and Research

RSS

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011

Hydromorphone can be as effective as diacetylmorphine in treating heroin addiction

A clinical trial to test better treatment options for chronic heroin addiction is expected to begin in Vancouver at the end of this year. Led by researchers from Providence Health Care and the University of British Columbia, it's the only clinical trial of its kind in North America.

13 Oct 2011

Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Lightlake Therapeutics Inc., an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

25 Aug 2011

FDA approves Cephalon's REMS for FENTORA, ACTIQ

Cephalon, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the Risk Evaluation and Mitigation Strategy (REMS) for FENTORA and ACTIQ.

22 Jul 2011

IAS, UIPHP to launch VKC for injecting drug users living with HIV

As a part of its new initiative, Expanding Access to Opioid Substitution Therapy (OST) for People Who Inject Drugs in Eastern Europe and Central Asia (EECA), the International AIDS Society (IAS) will launch a Virtual Knowledge Centre (VKC) in partnership with the Ukrainian Institute on Public Health Policy.

21 Jul 2011

Novel vaccine for treating heroin addiction

Researchers at The Scripps Research Institute have developed a highly successful vaccine against a heroin high and have proven its therapeutic potential in animal models.

21 Jul 2011

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Merck, known as MSD outside the United States and Canada, today announced final results from a Phase II clinical study, extending out to 240 weeks, of its integrase inhibitor ISENTRESS® (raltegravir) Tablets in combination therapy in previously untreated (treatment-naïve) adult HIV-1-infected patients.

18 Jul 2011

IAS, NIDA announce recipients of third annual joint research fellowships

The International AIDS Society (IAS) and the US National Institute on Drug Abuse (NIDA) today announced the recipients of their third annual joint research fellowships. Recipients of the prestigious awards will receive US$75,000 each to advance scientific understanding of the linkages between drug use and HIV while fostering multinational research.

13 Jul 2011

Roundup: Mass. doctors eye care management funds; Fla. groups fear Scott will block federal grants

It's clear from the data that hospitals and doctors can do a lot better at coordinating care for their patients. On the final day of hearings on controlling health care costs today, state officials estimated that at least $2 billion was spent in Massachusetts in 2009 on potentially avoidable emergency room visits, hospitalizations and readmissions.

2 Jul 2011

Centric Health to acquire DNPI Group assets

Centric Health Corporation, Canada's leading diversified healthcare company, today announced that it has entered into a definitive asset purchase agreement through a wholly owned subsidiary to acquire certain assets of Dedicated National Pharmacies Inc., Methadrug Clinic Limited and Union Medical Pharmacy Inc. from the court-appointed receiver of the DNPI Group, Grant Thornton Limited (the "Receiver").

27 Jun 2011

Drug addiction management costs UK £3.6bn a year: Report

According to a latest report from the think tank the Centre for Policy Studies (CPS), drug addiction costs £3.6bn a year for both treating problem drug users and keeping them on benefits. The study by has criticised government plans to change the way authorities tackle drug addiction. It claims the plans for payment-by-results schemes are “doomed to failure, not least because they are being run by the very organizations responsible for the current failure of policy”.

19 Jun 2011

Risky behavior, psychiatric disorders and substance abuse contribute to opioid overdose

Deaths related to prescription opioid therapy are under intense scrutiny, prompting those in pain medicine-clinicians, patient advocates, and regulators-to understand the causes behind avoidable mortality in legitimately treated patients.

13 Jun 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

More HIV infections linked to injection drug use in East Africa, report finds

Longer looks: Autism researcher's legacy; methadone for prisoners

Andrew Wakefield has become one of the most reviled doctors of his generation, blamed directly and indirectly, depending on the accuser, for irresponsibly starting a panic with tragic repercussions: vaccination rates so low that childhood diseases once all but eradicated here —whooping cough and measles, among them — have re-emerged, endangering young lives. And yet here he was in Texas, post-career-apocalypse, calmly discussing his work, and a crowd of around 250 people showed up to listen.

29 Apr 2011

Facts become greatest casualty in war on pain medications

The Florida Society of Pain Management Providers urges Government, Law Enforcement and the media to stop using false prescription drug data and statistics. The continued release of false and / or out of context information is solely intended to enflame the public. The misinformation that unfairly portrays Florida as ground zero in this issue has significant consequences for pain management patients and the physicians who provide legitimate care.

22 Apr 2011

Viewpoints: Gov. Walker on 'obsolete' Medicaid; Are patients consumers?; The Onion pokes fun at Romney

What does Medicaid have in common with "I Dream of Jeannie," "Lost in Space" and "Get Smart"? They all made their debut in 1965. ... the television networks have updated their programming.

22 Apr 2011

NIDA, ASAM launch new screening resources for primary care providers

A free, nationwide service was launched today to help primary care providers seeking to identify and advise substance-abusing patients.

11 Apr 2011

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced results from several new data analyses from the pivotal Phase III studies evaluating the addition of its investigational oral protease inhibitor VICTRELIS to peginterferon alfa-2b and ribavirin in adult patients with chronic hepatitis C virus genotype 1 infection.

1 Apr 2011

New research: Methadone can affect brain and impair intellectual functions

Methadone has been used to treat heroin addicts for nearly 50 years. Yet we have surprisingly incomplete knowledge about possible harmful effects from prolonged use. New research from the Norwegian Institute of Public Health shows that methadone affects the brain and impairs the attention of experimental animals.

24 Mar 2011